Results 141 to 150 of about 681,398 (156)

Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1/2 trial. [PDF]

Nat Med
Besse B, Lin JJ, Bazhenova L, Goto K, de Langen AJ, Kim DW, Wolf J, Springfeld C, Popat S, Lim DWT, Nagasaka M, Hong JY, Baik CS, Hervieu A, Moreno V, Yang N, Kollengode K, Yang H, Xu Y, Calvet CY, Yuan Y, Hammell AB, Drilon A, Solomon BJ.   +23 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Pyrizolo[1,5-]pyrimidine derivatives of the second-generation TRK inhibitor: Design, synthesis and biological evaluation

Bioorganic and Medicinal Chemistry Letters, 2022
Chunlei Tang, Yiqing Fan
exaly  

Discovery of quinazoline derivatives CZw-124 as a pan-TRK inhibitor with potent anticancer effects and

European Journal of Medicinal Chemistry, 2022
Dongmei Zhao, Qiaohua Qin
exaly  

Assessment of the toxicity and toxicokinetics of the novel potent tropomyosin receptor kinase (Trk) inhibitor LPM4870108 in rhesus monkeys

Regulatory Toxicology and Pharmacology, 2021
Jingwei Tian, Hongbo Wang, Liang Ye
exaly  

People also looked at

Frontiers in Oncology, 2022
Qian Chu, Jizong JIANG
exaly  

Discovery of ()--(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants

European Journal of Medicinal Chemistry, 2020
Jijun Wang, Zhenquan Hu, Jing Liu
exaly  

Canadian consensus on TRK-inhibitor therapy for NTRK fusion-positive sarcoma

International Journal of Cancer, 2021
Andrea J MacNeill, Christine E Simmons, Alannah Smrke   +2 more
exaly  

Gram-scale stereoselective synthesis of next generation of Trk Inhibitor LOXO-195

Tetrahedron Letters, 2022
Ling-Li Wang
exaly  

Expert Review of Clinical Pharmacology

Expert Review of Clinical Pharmacology, 2019
Noah C Federman, Ray McDermott
exaly